Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 18;31:09636897221083863. doi: 10.1177/09636897221083863

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — AMASCIS final study sample. Trial profile. Nineteen patients were initially randomized: 9 to the AD-MSC group and 10 to the placebo treatment group. In the AD-MSC group, two patients did not receive the study treatment because it could not be delivered on time for administration (2 weeks since symptom onset), and three developed exclusion criteria after randomization and before study treatment was applied. In the placebo group, only one patient developed exclusion criteria before treatment administration. Finally, AD-MSCs were administered to four participants and placebo to eight. One of these eight patients died before the end of the follow-up period. AD-MSCs: adipose tissue–derived mesenchymal stem cells; AMASCIS: Allogeneic Adipose Tissue–Derived Mesenchymal Stem Cells in Acute Ischemic Stroke.